THAR

Tharimmune, Inc. - Common Stock (THAR)

About Tharimmune, Inc. - Common Stock (THAR)

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Details

Daily high

$2.45

Daily low

$2.35

Price at open

$2.41

52 Week High

$9.08

52 Week Low

$0.95

Market cap

84.5M

Dividend yield

0.00%

Volume

179,817

Avg. volume

254,000

P/E ratio

-.62

Tharimmune, Inc. - Common Stock News